Global Analysis and Forecasts for Live Cell Imaging Market
Browse in-depth TOC on "Live Cell Imaging Market"
146 – Tables
40 – Figures
212 – Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163914483
The growing adoption of high-content screening techniques in drug discovery, rising incidence of cancer, and the growth in funding for research are the major factors driving the growth of this market.
"The reagents segment is expected for the largest share of the live cell imaging market in 2019."
Based on type, the live cell imaging consumables market is segmented into reagents, media, assay kits, and other consumables (microplates, slides, Petri dishes, coverslips, and culture chambers). In 2019, the reagents segment accounted for the largest share of 36.1% of the consumables market. The large share of this segment can primarily be attributed to the growing applications of biosciences and biotechnology within the pharmaceutical and healthcare fields. With advancements in technologies, the demand for high-quality reagents in biomedical research and processing is on the rise. The increasing demand for high-quality reagents and their repeated use in live-cell imaging procedures are also factors driving the growth of this market.
By technology, the high-content screening (HCS) segment is expected to grow at the highest CAGR during the forecast period."
Based on technology, the live cell imaging market is segmented into fluorescence resonance energy transfer (FRET), time-lapse microscopy, fluorescence recovery after photobleaching (FRAP), high-content screening (HCS), and other technologies. High-content screening (HCS) segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the increasing studies on cell behavior and the need to correlate multiple events and markers with cell morphology.
Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=163914483
"North America to hold the largest regional market share in 2019."
North America is expected to account for the largest share of the live cell imaging market in 2019, followed by Europe. The large share of North America can be attributed to factors such as the availability of government funding for life science research, drug development regulations, advances in live-cell imaging techniques, growth in the biotechnology and pharmaceutical industries, and the rising incidence of cancer.
The prominent players in this live cell imaging market are Danaher Corporation (US), Carl Zeiss AG (Germany), Nikon Corporation (Japan), Olympus Corporation (Japan), PerkinElmer, Inc. (US), GE Healthcare (US), Bruker Corporation (US), Thermo Fisher Scientific Inc. (US), Sartorius AG (Germany), Oxford Instruments (UK), BioTek Instruments (US), Etaluma, Inc. (US), CytoSMART Technologies (Netherlands), NanoEnTek Inc. (Korea), Phase Focus Limited (UK), Tomocube, Inc. (South Korea), Phase Holographic Imaging PHI AB (Sweden), BD Biosciences (US)
Currently, no effective treatment for COVID-19 is available in the form of vaccines or antiviral drugs, and patients are currently treated symptomatically. According to the WHO, there are 70 vaccine candidates under development, and three candidates are already being tested in human trials. At the forefront of the COVID-19 outbreak, many researchers worldwide are engaged in the viral research of SARS-CoV-2, the virus that causes COVID-19.
Live cell imaging systems, including advanced microscopy systems, help researchers investigate cellular behavior during viral research. Biomedical research requires the analysis of enormous amounts of data to develop vaccines. Therefore, major live cell imaging system providers, such as Leica Microsystems (Germany) and CytoSMART Technologies (Netherlands), have donated live cell imaging systems to assist COVID-19 researchers.
English
Arabic
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian